Prior exposure to AAV-CNGA3 or AAV-CNGB3
Pre-clinicalTerminated 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achromatopsia
Conditions
Achromatopsia
Trial Timeline
Jun 29, 2017 → Apr 4, 2024
NCT ID
NCT03278873About Prior exposure to AAV-CNGA3 or AAV-CNGB3
Prior exposure to AAV-CNGA3 or AAV-CNGB3 is a pre-clinical stage product being developed by MeiraGTx for Achromatopsia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03278873. Target conditions include Achromatopsia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03278873 | Pre-clinical | Terminated |
Competing Products
2 competing products in Achromatopsia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AAV - CNGB3 | MeiraGTx | Phase 1/2 | 33 |
| adeno-associated virus vector AAV- CNGA3 | MeiraGTx | Phase 1/2 | 33 |
Other Products from MeiraGTx
AAV RPE65Phase 1/2
33
AAV - CNGB3Phase 1/2
33
adeno-associated virus vector AAV- CNGA3Phase 1/2
33
AAV2hAQP1Phase 1
25
AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands)Phase 1
25